TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05271032

Intervention type: DIAGNOSTIC_TEST
Intervention: use of Trasnpulmonary termodiluetion technique
Description: All the patients underwent to invasive hemodynamic monitoring through the transpulmonary thermodilution technique (PiCCO, PULSION medical system. Gettinge; Solna, Sweden). Briefly, the technique consists in the administration of a cold saline bolus in superior vena cava while monitoring the corresponding temperature variation through a femoral arterial catheter equipped with a tip thermistor. Accordingly, a 5 French catheter equipped with a tip thermistor was inserted into the femoral artery.
Study: NCT01053728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form:Solution for injection~Route of administration: subcutaneous
Study: NCT02553980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow Your Virtual Trainer (FYVT) program
Description: Participants in intervention group will under the instruction of a web-based computer software termed Virtual Trainer, which interact with their smartphone apps, to conduct a 3-month self-planned PA training program. A serious of online video seminars related to healthy lifestyle advice will be released to the participants among 3 months. After that, 6 months observation will be followed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow Your Virtual Trainer (FYVT) program
Description: Participants in intervention group will under the instruction of a web-based computer software termed Virtual Trainer, which interact with their smartphone apps, to conduct a 3-month self-planned PA training program. A serious of online video seminars related to healthy lifestyle advice will be released to the participants among 3 months. After that, 6 months observation will be followed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Daily PA recommendation & healthy lifestyle suggestions
Description: A written advice of daily PA recommendation, and the textual content of the healthy lifestyle seminars will be provided to the participants.
Study: NCT03546595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupoints acupressure
Description: The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham auricular acupoints acupressure
Description: The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
Study: NCT02342717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: single dose BI 425809 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: multiple doses of Itraconazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: single dose BI 425809 tablet
Study: NCT02068690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 PfOS
Description: BI 425809 PfOS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 tablet
Description: BI 425809 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 PfOS
Description: BI 425809 PfOS
Study: NCT02182063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 high dose
Study: NCT01950793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone acetonide
Description: used ultrasound-guided inject 1c.c triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only Steroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: used ultrasound-guided inject 1c.c Hyaluronic acid (Artz®, Seikagaku, Japan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only
Study: NCT03929653

Intervention type: OTHER
Intervention: Personalized therapy model with Molecular Tumor Board and Next Generation Sequencing
Description: This study is to observe this therapy model outcomes
Study: NCT02570152

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: Blood samples will be collected during the Suspected Dengue First Visit. All study subjects with AFI (fever \[body temperature ≥ 38°C/≥ 100.4°F\] on ≥ 2 consecutive calendar days, measured at least twice, at least 8 hours apart) should be seen at a designated study hospital/clinic by the study physician. The Suspected Dengue First Visit should be scheduled within 7 days from the onset of fever (Days 2-7) and should ideally take place on the second day of fever (Day 2).
Study: NCT03564522

Intervention type: PROCEDURE
Intervention: cardiac catheterization
Description: cardiac catheterizations will be clinically indicated and the study will collect this clinical data.

Intervention type: PROCEDURE
Intervention: cardiac catheterization
Description: cardiac catheterizations will be clinically indicated and the study will collect this clinical data.

Intervention type: RADIATION
Intervention: Cardiac MRI
Description: If clinically indicated, the study will collect data from MRIs.

Intervention type: RADIATION
Intervention: Cardiac MRI
Description: If clinically indicated, the study will collect data from MRIs.
Study: NCT03913026

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transplant with an expanded ECT-001 cord blood
Description: 1. Patients will receive a conditioning regimen (such as: cyclophosphamide 120 mg/kg, fludarabine 75mg/m2 and TBI 12 Gy or cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, thiotepa 10 mg/kg and TBI 4 Gy).~2. The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.~3. Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus). Tacrolimus will be discontinued on Day 100 post-transplant unless GVHD arises.
Study: NCT02657655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesia 360
Description: Kinesia 360 includes a mobile app and wireless motion sensors worn on the patient's wrist and ankle to quantify tremor, dyskinesias, and mobility throughout the day as he or she goes about normal activities. The app includes electronic diaries enable patients to rate their symptoms and log when medications are taken. Data is transferred to a cloud server where motor symptom reports are generated for clinician review.
Study: NCT02017938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality anti-fatigue ergo cycling training (Self-made)
Description: To establish a Virtual Reality systems to reduce fatigue of cycling training for PD subjects.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality anti-fatigue ergo cycling training (Self-made)
Description: To establish a Virtual Reality systems to reduce fatigue of cycling training for PD subjects.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality anti-fatigue ergo cycling training (Self-made)
Description: To establish a Virtual Reality systems to reduce fatigue of cycling training for PD subjects.
Study: NCT01181999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: A dose of 375mg/m2 rituximab will be administered intravenously on day 1 of first to fourth R-CHOP chemotherapy and on day 1, 8, 15, 22 of each augmentation chemotherapy.
Study: NCT00839449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid ethyl ester
Description: Orally administered 900 mg eicosapentaenoic acid ethyl ester three times a day (2700 mg ⁄ day) from the surgery next day to 30 days after the onset of SAH.
Study: NCT02284529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orectalip
Description: Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1
Study: NCT03915574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25G Dural Puncture Epidural
Description: Dural puncture created with a 25 gauge spinal needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Epidural
Description: Control group - standard epidural (no dural puncture)
Study: NCT02842515

Intervention type: OTHER
Intervention: teeth avulsion
Study: NCT01213147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene citrate
Description: 100 mg per day oral for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buserelin
Description: 50 µg Subcutaneous twice a day from cycle day 2 of menstrual cycle
Study: NCT00923975

Intervention type: DEVICE
Group type: OTHER
Intervention: DIDGET World Web Community Reports
Description: During the study subjects performed specific tasks, such as uploading meter results to a secure website and displaying reports.
Study: NCT01328535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: staining method
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT05384418

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDP-Tc99m bone scintigraphy
Description: HDP-Tc99m bone scintigraphy
Study: NCT03554057

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Computed Tomographic Angiography
Description: All low-risk patients referred for invasive coronary angiography will be potentially eligible to receive the intervention over a 12-month period. The intervention will include risk stratification using Coronary Computed Tomographic Angiography (CCTA) at HHS and NHS as an alternative to upfront invasive angiography. All CCTAs will be read by both a level 3-trained cardiologist and a radiologist. The results of the CCTA, coupled with evidence-based management recommendations will be sent to the referring physician and an invasive angiogram will be arranged only when indicated as per these management recommendations
Study: NCT03224507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRdD followed by auto-HCT
Description: Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will be followed by autologous hematopoietic cell transplantation and KRdD consolidation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRdD only
Description: Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will not be followed by autologous hematopoietic cell transplantation but will proceed with KRdD consolidation.
Study: NCT00619424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Oral tablet administered daily in dosages of 400 - 800 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Oral tablet administered daily in dosages of 400 - 800 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: oral tablet taken daily in dosages of 100-150 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: IV chemotherapeutic agent administered every 21 days in dosages of 400-500 mg/m2
Study: NCT01032291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Intravenous infusions of cetuximab (400 mg/m\^2 Cycle 1 Day 1, thereafter 250 mg/m\^2), administered on days 1, 8, 15 and 22 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle
Study: NCT00660413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOF-Watch SX (Acceleromyography)
Description: Randomization of AMG to dominant or non-dominant arm. MMG at contralateral arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOF-Watch SX (Acceleromyography)
Description: Randomization of AMG to dominant or non-dominant arm. MMG at contralateral arm.
Study: NCT03699059

Intervention type: OTHER
Group type: OTHER
Intervention: ExeRTiOn
Description: REHAB-online is an online weight gain prevention tool comprising of physical activity advice, dietetic advice, self-monitoring and tracking and behavioural change techniques. This resource is specific to kidney transplant patients and has been created by the research steering group including patient representation. During this study participants (both HCPs and patients) will have a one-off study visit to test and evaluate the online intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: ExeRTiOn
Description: REHAB-online is an online weight gain prevention tool comprising of physical activity advice, dietetic advice, self-monitoring and tracking and behavioural change techniques. This resource is specific to kidney transplant patients and has been created by the research steering group including patient representation. During this study participants (both HCPs and patients) will have a one-off study visit to test and evaluate the online intervention.
Study: NCT03600636

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diffusion tensor imaging MRI
Description: 1. axial diffusion weighted sequence with 32 gradient encoding directions and two values b, 0 s / mm 2 and 1000 s / mm 2.~2. Fluid-attenuated inversion recovery~3. three-dimensional axial image weighted in T1~4. axial echo-planar image sequence~5. three-dimensional pulse sequence axial flight time

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diffusion tensor imaging MRI
Description: 1. axial diffusion weighted sequence with 32 gradient encoding directions and two values b, 0 s / mm 2 and 1000 s / mm 2.~2. Fluid-attenuated inversion recovery~3. three-dimensional axial image weighted in T1~4. axial echo-planar image sequence~5. three-dimensional pulse sequence axial flight time
Study: NCT02449889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: highly purified human chorionic gonadotropin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: highly purified human chorionic gonadotropin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human chorionic gonadotropin
Study: NCT03197714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-111077
Description: Two dose schemas will be employed:~* Level 1: 200 mg daily~* Level 2: 250 mg daily
Study: NCT00936910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amphotericin B liposomal (Ambisome)
Description: After enrollment, antifungal therapy will be instituted consisting of both systemic and antifungal lock therapy. Systemic therapy will be amphotericin B liposomal (Ambisome) administered IV in a dose of 3-5 mg/kg/day (or other antifungal based upon standard of care) combined with antifungal lock therapy. The antifungal lock therapy consists of placing sufficient amphotericin B liposomal (Ambisome \[2 mg/ml\]) lock solution into the infected central venous catheter (CVC) and allowing it to dwell uninterruptedly for 8 to 12 hours per day for 10-14 days (largest CVC = 2.3 mL).
Study: NCT03171623

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: globalagliatin hydrochloride
Description: orally administration, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: globalagliatin hydrochloride
Description: orally administration, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: globalagliatin hydrochloride
Description: orally administration, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: globalagliatin hydrochloride
Description: orally administration, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: globalagliatin hydrochloride
Description: orally administration, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally administration, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally administration, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally administration, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally administration, single dose
Study: NCT00797745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
Study: NCT03495076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline injection
Description: In the saline injection condition, acute neck pain will be induced via 0.5 ml hypertonic (5% NaCl) saline bolus injection which is a commonly used model of acute pain. Saline will be injected into the right (or left) trapezius muscle at the level of C7 cervical level. Injections will be performed by a physician under ultrasound imaging guidance to ensure that each single injection will be equally placed at the same depth. The side for the pain induction will be randomised across subjects. The place of needle insertion and corresponding point on the opposite side of the body will be covered by placing a small piece of adhesive plaster to ensure blinding.
Study: NCT03495076

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: In the sham-injection condition (nocebo comparator), a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience. A pinprick sensation will be produced by a weighted stimulus applied perpendicularly to the skin without piercing the skin. A stimulus of 512 millinewtons (mN) will be used to produce a pinprick sensation and activation of cutaneous nociceptors. Adhesive tapes covering stimulation points will also be provided. The stimuli will be applied in exactly the same spot as the real injection in previous experimental condition.
Study: NCT00797745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
Study: NCT05076916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The effectiveness of the web-based education programme among cancer patients
Description: The web-based education program was introduced to the patients with cancer in the intervention group during face-to-face interviews. They were asked to examine the program for at least two hours a week for three months. During the follow-up period, the patients in the intervention group were called twice a week and reminded to use the education program. The researchers get in contact with the patients online via the website. The patients contact the research team by calling or writing messages via the website 24/7. An e-mail account was created by the research team using the email system of the university, and it was shared with the patients. The clinical researchers of the team answered the patients' questions via this e-mail account.
Study: NCT01415648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cerebral oximetry monitoring using INVOS™ and hemodynamic optimisation
Description: continuous per operative cerebral oximetry monitoring associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: standard cerebral monitoring and hemodynamic optimisation
Description: the patient is continously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre.
Study: NCT00182052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Given orally twice daily. Participants may continue study treatment as long as their disease does not progress and they don't experience any serious side effects.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally twice daily.
Study: NCT00953446

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging
Description: Performed at baseline, 2 weeks upon initiation of therapy, after cycle 2 and/or cycle 4 of therapy, and at the end of treatment
Study: NCT03857191

Intervention type: DIETARY_SUPPLEMENT
Intervention: Nutritional psychocomportemental rehabilitation
Description: Nutritional psychocomportemental rehabilitation

Intervention type: DIETARY_SUPPLEMENT
Intervention: Nutritional psychocomportemental rehabilitation
Description: Nutritional psychocomportemental rehabilitation

Intervention type: DIETARY_SUPPLEMENT
Intervention: Nutritional psychocomportemental rehabilitation
Description: Nutritional psychocomportemental rehabilitation
Study: NCT04351464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy and reflexology

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy and reflexology
Study: NCT04154449

Intervention type: DRUG
Intervention: Intranasal insulin
Description: Surgical group Received intranasal insulin, the second group surgical Received placebo and the third group is non surgical do not receive anything.
Study: NCT01194089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Nicotine Spray
Description: Single 3 mg dose of nasal nicotine spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Normal Saline Spray
Description: An isotonic solution of sodium chloride 0.65% in deionized water